65,437 trials
Breast Cancer
Primary: Clinical Response (Complete or Partial Response) Rate (Cohort A) — 62.9; 74.8; 69.1 percentage of patients
Asthma Placebo Effects
Primary: Change in FEV1 — 20.1; 7.5; 7.3; 7.1 percentage change in FEV1
Satisfaction
Primary: Anxiety — 2.9; 1.4 NRS
Chemotherapy-induced Nausea and Vomiting
Primary: Proportion of Participants Receiving HEC With Complete Response in Overall Phase — 20; 15 Participants — p=0.397
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations Above the Cut-offs — 61; 5; 17; 0 Subjects
Chronic Obstructive Pulmonary Disease
Primary: Sleeping Oxygen Saturation — 94.4; 94.4 percentage of Oxygen Saturation — p=0.88
End-Stage Renal Disease · Stage 5 Chronic Kidney Disease
Primary: Cmax of Telavancin — 33.1; 38.1 mcg/mL
Type 1 Diabetes Mellitus
Primary: The Primary Treatment Comparison is the Evaluation of the Duration (Minutes) of Induced Hypoglycemia. — 138.5; 170.7 minutes — p=0.006
Cocaine Dependence
Primary: Immediate Memory Task
Obesity · Body Weight · Overweight
Primary: Number of Participants With Adverse Events — 5; 2; 0; 13 Participants
Depression
Primary: Percentage Change in Quick Inventory of Depressive Symptomatology (QIDS-C16) Score From Baseline — -41.2; -11.0; -48.4; -31.8 Percentage change in depression rating…
Hip Fracture
Primary: Feasibility - # With > or = 60% Compliance, # Agreeing to Participate, # Returning for 3 Month Follow-up — 14; 10; 6 Participants
Autistic Disorder
Primary: Number of Participants With Adverse Events According to Dosage Record and Treatment Emergent Symptom (DOTES) as Assessed at All Follow-up Visits (2, 4, 6, 8, 10, 12, and…
Stroke
Primary: Change in Peak Aerobic Capacity (VO2-peak) — 2.2; -1.3 ml/kg/min
Cholangiocarcinoma
Primary: The Primary Objective of This Study is to Assess Progression Free Survival (PFS) With Proposed Therapy for Patients With Locally Advanced or Metastatic Gallbladder and…